FIELD: biotechnology.
SUBSTANCE: completely human antibody or its fragment is proposed, which specifically bind to an extracellular domain of a receptor tyrosine kinase-like orphan receptor 2 (ROR2). Antibody-drug conjugates including antibodies according to the invention are also proposed. In addition, the use of the specified conjugates in a method for the treatment of a neoplastic disease, as well as in a method for determination of a neoplastic disease or an immune disease in a patient or the risk of its development is disclosed.
EFFECT: invention can be used in cancer therapy.
17 cl, 11 dwg, 14 tbl, 10 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS OF ANTIBODIES AGAINST ROR1 AND CORRESPONDING METHODS | 2017 |
|
RU2766190C2 |
| FUSED PROTEIN CONSTRUCTS FOR COMPLEMENT-RELATED DISEASE | 2019 |
|
RU2824402C2 |
| CONNECTIVE TISSUE GROWTH FACTOR ANTIBODY AND USE THEREOF | 2020 |
|
RU2819228C2 |
| BISPECIFIC ANTIBODY AGAINST RABIES VIRUS AND ITS APPLICATION | 2019 |
|
RU2764740C1 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| ANTIBODY CAPABLE OF BINDING TO THYMIC STROMAL LYMPHOPOIETIN, AND USE THEREOF | 2020 |
|
RU2825304C2 |
| CYTOTOXICITY-INDUCING THERAPEUTIC AGENT | 2015 |
|
RU2743464C2 |
| ANTI-PCSK9 ANTIBODY, ITS ANTIGEN-BINDING DOMAIN AND MEDICAL APPLICATION THEREOF | 2016 |
|
RU2739208C2 |
| CD40 LIGAND THERAPEUTIC ANTIBODIES | 2018 |
|
RU2770209C2 |
| HIGH-AFFINITY ANTI-PD-1 AND ANTI-LAG-3 ANTIBODIES AND BISPECIFIC BINDING PROTEINS OBTAINED FROM THEM | 2019 |
|
RU2782381C2 |
